12 patients won't be enough to approve MPL for global use but it should be enough to gain the orphan drug designation.
If companies have less than 2 quarters of funding they just need to answer a few extra questions in their quarterly report. I've held a few companies that have done this without consequence.
12 patients won't be enough to approve MPL for global use but it...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.005(2.38%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.5¢ | 21.0¢ | $325.8K | 1.512M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 236217 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 78289 | 2 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
0.005 ( 2.23 %) |
||||
| Open | High | Low | Volume | ||
| 21.5¢ | 22.5¢ | 21.0¢ | 629786 | ||
| Last updated 15.58pm 03/06/2024 ? | |||||
| PAA (ASX) Chart |